Edge Wealth Management LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 2.2% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 76,445 shares of the company's stock after selling 1,704 shares during the period. Johnson & Johnson makes up about 2.2% of Edge Wealth Management LLC's investment portfolio, making the stock its 18th largest position. Edge Wealth Management LLC's holdings in Johnson & Johnson were worth $11,055,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of the company. Werlinich Asset Management LLC grew its position in Johnson & Johnson by 1.5% in the fourth quarter. Werlinich Asset Management LLC now owns 13,330 shares of the company's stock valued at $1,911,000 after acquiring an additional 200 shares in the last quarter. Cohen Investment Advisors LLC grew its position in Johnson & Johnson by 2.6% in the fourth quarter. Cohen Investment Advisors LLC now owns 19,530 shares of the company's stock valued at $2,824,000 after acquiring an additional 490 shares in the last quarter. Congress Park Capital LLC grew its position in Johnson & Johnson by 16.4% in the fourth quarter. Congress Park Capital LLC now owns 8,153 shares of the company's stock valued at $1,179,000 after acquiring an additional 1,151 shares in the last quarter. Inspirion Wealth Advisors LLC grew its position in Johnson & Johnson by 7.3% in the fourth quarter. Inspirion Wealth Advisors LLC now owns 1,775 shares of the company's stock valued at $260,000 after acquiring an additional 120 shares in the last quarter. Finally, Tallon Kerry Patrick acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $290,000. Institutional investors and hedge funds own 69.55% of the company's stock.
Insider Buying and Selling at Johnson & Johnson
In related news, Director Mark A. Weinberger acquired 1,000 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.16% of the stock is currently owned by company insiders.
Johnson & Johnson Stock Performance
JNJ stock traded down $0.74 during mid-day trading on Friday, reaching $147.03. The company had a trading volume of 10,678,393 shares, compared to its average volume of 6,880,262. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $353.99 billion, a P/E ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 0.51. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The stock's 50-day simple moving average is $148.68 and its two-hundred day simple moving average is $155.96.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analysts' expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm's quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the business posted $2.66 earnings per share. Research analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current year.
Johnson & Johnson Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.37%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's payout ratio is 71.78%.
Analyst Ratings Changes
A number of analysts have recently weighed in on the stock. Guggenheim raised their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 6th. Royal Bank of Canada raised their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 16th. Wolfe Research assumed coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an "outperform" rating and a $190.00 price target for the company. Bank of America decreased their price target on shares of Johnson & Johnson from $166.00 to $160.00 and set a "neutral" rating for the company in a research report on Friday. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $174.29.
View Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Articles
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
